Cinnarizine is a piperazine-class calcium channel blocker and H1-receptor antagonist that reduces labyrinthine excitability, used for the management of vestibular disorders such as vertigo, Meniere's disease and motion sickness. Simson Pharma's Cinnarizine reference standard and impurities support compendial testing for this anti-vertigo therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cinnarizine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.